Aptose Biosciences Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Aptose Biosciences Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2017 to Q2 2024.
  • Aptose Biosciences Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$7.25M, a 48.7% increase year-over-year.
  • Aptose Biosciences Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$40.3M, a 15.3% increase year-over-year.
  • Aptose Biosciences Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$51.2M, a 22.4% decline from 2022.
  • Aptose Biosciences Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$41.8M, a 36% increase from 2021.
  • Aptose Biosciences Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$65.4M, a 18.3% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$40.3M -$7.25M +$6.88M +48.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$47.2M -$9.64M +$4.04M +29.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$51.2M -$12M -$1.96M -19.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-26
Q3 2023 -$49.3M -$11.4M -$1.67M -17.1% Jul 1, 2023 Sep 30, 2023 10-K 2024-03-26
Q2 2023 -$47.6M -$14.1M -$3.56M -33.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$44M -$13.7M -$2.2M -19.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$41.8M -$10M +$14.3M +58.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-26
Q3 2022 -$56.1M -$9.78M +$1.56M +13.7% Jul 1, 2022 Sep 30, 2022 10-K 2024-03-26
Q2 2022 -$57.7M -$10.6M +$2.91M +21.6% Apr 1, 2022 Jun 30, 2022 10-K 2024-03-26
Q1 2022 -$60.6M -$11.5M +$4.75M +29.2% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-26
Q4 2021 -$65.4M -$24.3M -$9.61M -65.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-24
Q3 2021 -$55.7M -$11.3M +$1.92M +14.5% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-24
Q2 2021 -$57.7M -$13.5M +$2.28M +14.5% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-24
Q1 2021 -$59.9M -$16.2M -$4.7M -40.8% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-24
Q4 2020 -$55.2M -$14.7M -$7M -90.9% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-22
Q3 2020 -$48.2M -$13.2M -$6.41M -93.6% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-22
Q2 2020 -$41.8M -$15.8M -$9.53M -153% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-22
Q1 2020 -$32.3M -$11.5M -$6.02M -109% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-22
Q4 2019 -$26.3M -$7.71M -$1.45M -23.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-23
Q3 2019 -$24.8M -$6.84M -$1.31M -23.7% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-23
Q2 2019 -$23.5M -$6.22M +$4.04M +39.4% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-23
Q1 2019 -$27.6M -$5.51M +$1.31M +19.2% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-23
Q4 2018 -$28.9M -$6.26M -$2.99M -91.5% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-10
Q3 2018 -$25.9M -$5.53M -$2.89M -110% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-10
Q2 2018 -$23M -$10.3M -$7.82M -320% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-10
Q1 2018 -$15.2M -$6.81M -$3.52M -107% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-10
Q4 2017 -$11.6M -$3.27M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$2.64M Jul 1, 2017 Sep 30, 2017 8-K 2019-03-12
Q2 2017 -$2.44M Apr 1, 2017 Jun 30, 2017 8-K 2019-03-12
Q1 2017 -$3.29M Jan 1, 2017 Mar 31, 2017 8-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.